1 INTRODUCTION

The isoxazoline class of compounds are ligand-gated ion channel inhibitor parasiticides that have been developed for at least 20 years (Garcia-Reynaga, Zhao, Sarpong, & Casida, 2013; Nakata et al., 2017; Ozoe, Ozoe, Nakahira, & Mita, 2010; Quan et al., 1999; Shoop et al., 2014; Zhao & Casida, 2014). When initially designed and synthesized as a series of bisbenzamide isoxazolines by Dupont Pharmaceuticals, their purpose was to act as antithrombotic agents that inhibit the activity of
coagulation factor Xa, although side effects included excessive bleeding and hemolysis (Quan et al., 1999). The earlier reports of these synthesized compounds and their mechanisms of action laid the groundwork for subsequent pre-clinical studies as parasiticides, which were described in a special issue of Veterinary Parasitology in 2014 (Drag, Saik, Harriman, & Larsen, 2014; Shoop et al., 2014). Subsequent to their development as parasiticides, they are now widely used throughout the world and are considered by most to be efficacious and safe, even in 8-week old puppies (Drag et al., 2014; Kuntz & Kammanadiminti, 2017). However, despite the estimated millions of doses being given, adverse events (AE) that had previously been believed to be rare (Gaens, Rummel, Schmidt, Hamann, & Geyer, 2019; Quan et al., 1999), post-marketing AE have been increasingly reported since the release of these products.

More recently, Gaens et al. (2019) reported suspected transient neurotoxicity in a 7-month old female Danish spaniel (Kooikerhondje) puppy. About 24 hr after administering fluralaner, she exhibited generalized ataxia, myoclonic jerks, tremor of the head and body, muscle twitching and oral dysphagia; she fully recovered after 10 hr without treatment (Gaens et al., 2019). Factors including genetic predisposition that could predispose an individual animal to AE are unknown, although the effects of an MDR1 efflux carrier at the blood-brain barrier could play a role (Saidijam, Dermani, Sohrabi, & Patching, 2017).

The impetus for the present survey inquiry into the potential AE associated with the use of canine flea and tick treatments was prompted by non-AE documented reports and clinical experiential AE reports from veterinarians and pet owners worldwide. These reports were apparently disregarded or failed to generate concern and responsiveness from the manufacturer(s), which was compounded by the failure to report serious AE on their package labelling, until recent label changes were made from 2018 to 2019. Consequently, the present team of experts was formed to gain an objective understanding of any toxic effects that may be related to the isoxazolines.

Isoxazolines exhibit killing activity through effects on the nervous system. Isoxazoline efficacy is based on their modality as non-competitive GABA (gamma-aminobutyric acid) receptor antagonists that are putatively much more selective for GABA receptors in fleas or ticks, than for those in mammals, including humans (Gassel, Wolf, Noack, Williams & Ilg, 2014; Shoop et al., 2014). They bind to arthropod gamma-aminobutyric acid (GABA)-gated chloride channels (GABACls) in nerve and muscle cells, which blocks the transmission of neuronal signals. Some of the currently registered isoxazolines claim an adequate safety margin for canine and feline administrations and that the mechanism of action is insect-specific. However, although some recently marketed isoxazoline package inserts do mention seizures or other neurotoxic effects, these effects, including death, are not insect-specific. The purpose of the current study was to perform an independent survey to document the use and safety of the isoxazoline parasiticides pre- and post-administration.

2 | METHODOLOGY

2.1 | Survey

A Survey questionnaire instrument was developed in conjunction with the Project Jake team. It was distributed electronically by mail throughout the United States to veterinarians, veterinary clients, pet caregivers/owners, kennel club groups and on social media sites between August 1 and 31, 2018. The questionnaire addressed the respondent’s use of a parasiticide for flea and/or tick control on their dogs pre- and post-administration. We chose to focus just on the dog initially rather than including cats. While a reporting bias can arise for participants of this type of survey, respondents were encouraged to complete initial questions even if they had not seen or were unaware of any AE from the use of isoxazoline or other flea or tick preventive compounds. Pitfalls of electronic online surveys include: absence of interviewer input, may not effectively reach the intended population, and survey bias or fraud (Evans & Mathur, 2018; Nayak & Narayan, 2019; Rice, Winter, Doherty, & Milner, 2017; Vaske, 2011). The authors acknowledge these potential shortcomings of the survey instrument, but believe that the findings described herein reflect valid concerns. In addition to the survey data shown here, the findings were compared to the reported FDA and EMA data. Freedom of Information Act (FOIA) requests were sent to the FDA concerning their isoxazoline AE reports (see Appendix, #1–8). For the EMA reports, the findings reported by the Committee for Medicinal Products for Veterinary Use (CVMP) at the meeting of 5–7 September 2017 were used. These represented the CVMP Cumulative Reports from Jan 2013 to Sept 2017 (see Appendix, #9). An analysis of the occurrence of AE was conducted to compare the number of Project Jake AE, with the FDA and EMA AE pharmacovigilance reports, as listed in the Appendix, #1–9.

2.2 | Data analysis and limitations

Analysis of the survey data and of reports made to regulatory agencies consists of event tabulations and summary calculations of percentages of occurrence for AE with a focus in the present summary on serious neurologic effects and deaths reported in canines. Statistical analysis was made for the severe AE of: death, seizures and convulsions, and ataxia, instability and imbalance by comparing the two-tailed Z-test differences between the Project Jake survey with those reported by the FDA and EMA. The number of reports represents the number of AE received for a particular drug and do not infer the relative toxicity between drugs. AE reports should not be used to calculate incidence rates or estimates of drug risk, since there is no accurate way to determine how many animals were actually given the drug, which is needed as the denominator in calculations of incidence and relative risk. Beyond the manufacturer’s advertising and marketing materials, there is no indication of how many of the products have been sold. Furthermore, neither the FDA nor EMA address the total doses or treatments given in their data,
and the package inserts do not delineate how many animals were treated and how many had serious AE (Tables 2-4, 7, 8; Appendix).

Since an AE may have been related to an underlying disease, use of other drugs at the same time, or other non-drug related causes, these circumstances create uncertain causality between the adverse event and treatment with the drug. The frequency of reporting for a given product may vary over time and may be higher when the drug is newly marketed, or when media publicity occurs, thus underreporting generally occurs with most AE reporting systems.

Regulatory AE reporting systems as well as the Project Jake survey are all voluntarily reported with inherent biases weighted towards adverse effects, since few pet caregivers/owners or veterinarians have cause to report the absence of side effects. However, the Project Jake survey included questions and responses about drug treatment with or without the observation of AE, and thus it provided a population of responders registering treatment without AE. In fact, 36.1% of the Project Jake survey respondents indicated that they did not see any AEs and another 8.2% were unsure (Table 1).

### TABLE 1  Summary of Project Jake Survey Respondent Numbers and Treatments

| Summary: Isoxazoline Survey - August 1–31, 2018 |
|-----------------------------------------------|
| Total Respondents: 2,751                      |
| Respondents who gave their dog any flea treatment: 1594 57.9% |
| Respondents who gave their dog an isoxazoline treatment: 1,325 48.2% |

#### Which Isoxazoline?

- Fluralaner (Bravecto) 911 68.8%
- Afoxolaner (Nexgard) 342 25.8%
- Sarolaner (Simparica) 72 5.4%

#### Did the dog experience a reaction to any treatment?

- Yes 1,062 66.6%
- No 576 36.1%
- Unsure 130 8.2%

#### Respondents whose dogs experienced a reaction to Isoxazolines:

- Fluralaner (Bravecto) 791 86.8%
- Afoxolaner (Nexgard) 235 68.7%
- Sarolaner (Simparica) 44 61.1%

#### Products

| Products                            | N   | % of Responses |
|-------------------------------------|-----|----------------|
| Bravecto (fluralaner)               | 911 | 33.12%         |
| Nexgard (afoxolaner)                | 342 | 12.43%         |
| Simparica (sarolaner)               | 72  | 2.62%          |
| Advantage/Advantage II/ Advantage Multi | 26 | 0.95%          |
| Advantix/Advantix II                | 59  | 2.14%          |
| Advocate                            | 13  | 0.47%          |
| Comfortis                           | 29  | 1.05%          |
| Frontline/Frontline Plus            | 198 | 7.20%          |
| Kin and kind                        | 19  | 0.69%          |
| More than One Product               | 45  | 1.64%          |
| Other (exclusively)                 | 90  | 3.27%          |
| Revolution                          | 22  | 0.80%          |
| Sentinel                            | 23  | 0.84%          |
| Seresto collar                      | 36  | 1.31%          |
| Trifexis                            | 19  | 0.69%          |
| Vectra/Vectra 3D                    | 16  | 0.58%          |
| Wondercide                          | 15  | 0.55%          |

Note: Fluralaner, C22H17Cl2F6N3O3 - PubChem; Afoxolaner, C26H17ClF9N3O3 - PubChem; Sarolaner, C23H18Cl2F4N2O5S -PubChem; Lotilaner, C20H14Cl3F6N3O3S-PubChem; Lotilaner, C20H14Cl3F6N3O3S-PubChem; Lotilaner, C20H14Cl3F6N3O3S-PubChem;
Also, because the FDA CVM and EMA ADE reporting systems depend upon the voluntary reporting of adverse clinical events by veterinarians and animal caregiver/owners, as well as the mandatory reporting of AE by manufacturers, aggregate AE reports potentially may include duplicative reported events.

3 | RESULTS

The canine products with the largest number of survey responses from the FDA, EMA and Project Jake survey were afoxolaner (Nexgard®, Frontline Vet Labs™, Div. Merial Inc., Duluth, GA) and fluralaner (Bravecto®, Merck Animal Health, Madison, NJ) (Tables 1-8). Other isoxazoline products that were reported in smaller numbers were sarolaner (Simparica™, Zoetis Inc, Kalamazoo, MI) and lotilaner (Credelio™, Elanco US, Greenfield, IN) (Tables 1-9, Figure 1). Another reported product in both the FDA and EMA AE reports was spinosad, a different class of drug (Comfortis®, Elanco US, Greenfield, IN). (Tables 2 and 8).

3.1 | FDA and EMA adverse reaction (AE) reports (Tables 2-4; Appendix)

The authors reviewed FDA and EMA reported AE available via public access of FOIA-requested FDA AE reports (in Appendix; #1-8) and the updated EMA AE reports (Appendix, #9). An analysis of these AE types is presented in Table 2 and the subsequent Tables (3–7), and includes analysis of FDA, EMA and Project Jake survey results with a particular focus on the most severe AE, namely, death and neurological effects (Tables 6-9).

FDA reportable AE events from January 2013 to September 2017 are listed in Tables 2 and 3. These data show 32,374 reportable AE in dogs for this time period, with deaths (2.4 and 2.5%) and seizures (6.9 and 2.8%) for the isoxazolines afoxolaner (Nexgard®, Frontline Vet Labs™, Div. Merial Inc., Duluth, GA) and fluralaner (Bravecto®, Merck Animal Health, Madison, NJ), respectively, while sarolaner (Simparica™, Zoetis Inc, Kalamazoo, MI) had 3.2% deaths and 20.5% seizures. Lotilaner (Credelio™, Elanco US, Greenfield, IN) and spinosad (Comfortis®, Elanco US, Greenfield, IN) data were not available at the time of this analysis. Comparing the same time period (January 2013-September 2017), EMA isoxazoline AE reports (7,074, Table 4) were approximately one-fourth of the number of FDA reports, there were approximately 3 to 10 times the number of severe AE for these isoxazolines (Tables 3 and 4) shown in the FDA AE (32,374) reports. However, the EMA AE cumulative reportable events were updated in January 2019 and there are now 39,148 EMA AE reports from January 2013 to January 2019 (Table S1), which reflects about a fourfold increase from September 2017 to January 2019. During this extended reporting period, EMA data reflected notably higher serious AE for the four isoxazolines, ranging from 4.76% to 28.6% for deaths and 9.0 to 55.1% for seizure observations. Note that these EMA data included AE results for spinosad (6,080, Tables 8 and Table S1) with death (30.9%) and seizure (24%) rates markedly higher than serious AE rates for fluralaner, afoxolaner and sarolaner. The AE considered most serious with respect to neurological toxicity are listed at the top of Tables, 3-6, and the remaining reported AE are generally grouped by percentage occurrence and physiologic significance.

3.2 | Serious AE findings from the FOIA-requested CVM comprehensive clinical detail report listing (for comparable cumulative date range of January 2013 to September 2017)

These data are presented in Tables 3 and 8. Deaths for the fluralaner, afoxolaner and sarolaner isoxazolines in the FDA AE reports ranged from 2.5% to 3.2%. However, seizures, trembling and ataxia ranged from 2.8% to 7.5% for afoxolaner and fluralaner but were markedly higher for sarolaner at 20.50 and 41.1% (Tables 2, 3 and 8). Additionally, behavioural, cognitive and muscular AE observations for sarolaner were ~ 1.5 to 2 times higher than those noted for afoxolaner and fluralaner (Table 3).

Findings from the EMA AE reports for the same date range of January 2013 to September 2017 are presented in Table 4. There were 7,074 AE reported compared with the FDA reports of 32,374 in the same period; FDA reports showed about 3.4 to 6.1 times the number of EMA AE for these isoxazolines. The EMA AE considered most serious with regard to neurological toxicity are shown at the top of the Table 4, in similar placement to Table 3 for the FDA AE data. Of major significance was the fact that deaths in the EMA data were approximately 7 to 10 times higher than those reported in the corresponding time period to the FDA. Serious AE for seizure and tremor events in the EMA data were also notably higher than those reported to the FDA (Table 4). Furthermore, sarolaner reports were markedly higher than for afoxolaner and fluralaner, while the behavioural, cognitive and muscular AE observations in the EMA report data for sarolaner were similar to those noted for afoxolaner and fluralaner.

In comparing the updated cumulative data became available from the EMA for the extended period of January 2013 to January 2019.
The overall number of EMA AE reports (39,148) for afoxolaner, fluralaner and sarolaner in this update was essentially the same as those of the FDA events (32,374), as shown on Tables 2 and 3. Additionally, death and seizure reports for lotilaner and spinosad became available and are listed on Tables 2 and 8 for comparison. This larger EMA data set, which included an additional 15 months of reports, shows death and seizure events for afoxolaner comparable to the FDA findings with over 32,000 reported events. But, fluralaner and sarolaner EMA reported death and seizure events remained approximately 7 to 10 times higher than the reported FDA events. Remarkably, the death and seizure reports for lotilaner and spinosad were also about 10 times higher than those reported in the FDA data for the isoxazolines (Table 8).

A relationship between the occurrence of death and/or seizures was examined for the EMA cohort data from the January 2013 to September 2017 period versus January 2013 to January 2019 (Table S1). Comparing these two time periods, not only is there a substantial increase in AE reports, but the percentage of seizures and deaths is still remarkable even with a larger data set. The death rate range per isoxazoline type for 2013–2017 was 13%–24% versus 5%–31% for 2013–2019. The seizure rate range per isoxazoline type for 2013–2017 was 19%–60% versus 9%–55% for 2013–2019. The major difference in the two data sets is the type of isoxazoline used with the increase in afoxolaner use, and the introduction of new isoxazolines. These data indicated that not all dogs with seizures died, but the converse result could not be determined. With respect to pet age, serious AE showed death reported in about 60% of dogs older than 5 years with seizures in more than 50% of dogs older than 5 years (Table 9). An analysis of possible concurrent disease or health status was not possible for this data set. An analysis of the reported death and seizure AE associated with product dosage was inconclusive, although the data suggested that these serious AE occurred at most dosages and the Fluralaner dose of 1,000 mg appears to be an outlier, with 310 reports of seizures (30%) and 379 reports of death (38%), some of these could be the same animal, of which cannot be confirmed. (Table S2). The most serious AE as stated in the EMA cumulative reports were observed at 0–24 hr after the first dose, and then again after the second and third doses (Figure 1), which was consistent with the known isoxazoline pharmacokinetics of absorption and elimination following administration of oral chews (Letendre et al., 2014). Additionally, the pharmacokinetics and half-life of isoxazolines were discussed by Drag et al. (2014).

### 3.3 Project Jake survey AE reports (Tables 1, 5, 6)

The Project Jake survey data results are shown in Tables 1, 5 and 6 and consolidated in Table 8, in comparison to the FDA and EMA data. Table 1 lists the survey findings for isoxazolines and an array of other topical flea and tick parasiticide products administered by survey responders; the number (N) of treated pets shows the percentages of the total number of responders (2,751). For the 12 topical formulations of flea and tick preventives listed in Table 1, there were 450 respondents that used them. Of these 450 responses, the number using them varied from 2.9% to 22.7%, with another 10% using a combination of them and 1.1% unsure what was used.

### Table 2

| 2018 Label Side Effects Listed<sup>a</sup> |
|------------------------------------------|
| Afoxolaner (Nexgard)                     |
| Vomiting, decrease appetite, diarrhea, lethargy, polydipsia, flatulence; contains a caution about use in dogs with a history of seizures. |
| Fluralaner (Bravecto)                    |
| Vomiting, decrease appetite, diarrhea, lethargy, polydipsia, flatulence; label recently expanded to include seizures |
| Sarolaner (Simparica)                   |
| Vomiting, seizure, lethargy, diarrhea, tremor, ataxia; “may cause abnormal neurologic signs such as tremors, ataxia,... Seizures” |

### FDA Adverse Reaction Reports<sup>1–8</sup>

| 32,374 Adverse Event Reports in Dogs with 801 Deaths and 1728 Seizures |
|-----------------------------------------------------------------------|
| Product (Reports), Deaths/%, Seizures/% |
| Afoxolaner (14,116), 341/2.4%, 981/6.9% |
| Nexgard<sup>1–8</sup>                                                 |
| Fluralaner (16,896), 416/2.5%, 468/2.8% |
| Bravecto<sup>1–8</sup>                                                |
| Sarolaner (1,361), 44/3.2%, 279/20.5% |
| Simparica<sup>1–8</sup>                                               |

*Note: Lotilaner (Credelio) AE reports were not available via FOIA due to the newness of this drug Spinosad (Comfortis) AE reports not available at time of analysis.

<sup>1–8</sup>FOIA: CVM ADE Comprehensive Clinical Detail Report Listing, Cumulative Date Range: Jan-2013 - Sept-2017.

<sup>9</sup>From EMA – cumulative reports from Jan 2013 - Jan 2019.

<sup>a</sup>Package Inserts are available in Appendix B.
Tables 1 and 5 also show that of the 2,751 total Project Jake survey responders 57.9% (1,594) had treated their pet dogs with a flea and tick product whereas 42.1% (1,157) of responders replied “No, Unsure, or failed to respond to this question”. Because of the nature of the survey question posed, we couldn't determine how many AE responders reported “Unsure” - for the time of exposure to the AE. Responses in Table 1 that included dogs treated with an isoxazoline flea/tick product showed that 48.2% (1,325) were given either fluralaner (68.8%), afoxolaner (25.8%) or sarolaner (5.4%). Lotilaner data were not included in the responses for this survey since it was new to the market at that time. Of the 1,594 dogs receiving any brand of flea & tick remedy 66.6% recorded some type of reported AE (Table 1). For dogs treated with an isoxazoline, 86.8% of fluralaner treated pets experienced a reaction; whereas 68.7% given afoxolaner and 61.1% of sarolaner treated dogs had a reaction following these treatments. Of those responders who treated their dogs with isoxazolines (1,325) 80.1% reported adverse effects in their pets. Serious AE were noted in 4.55 to 14.79% of animals given isoxazolines (Tables 5 and 6). Fluralaner and afoxolaner had reports of 11.91 to 14.79% seizures and deaths (Table 5). Sarolaner statistics were circumspect since the number of respondents was very limited.
The number of dogs with both seizures and death suggests a potential progression of symptoms as shown in Table 6. When examined for dogs that experienced seizures and death the data reveal that for fluralaner and afoxolaner approximately 20 to 46% of dogs that had seizures/tremors subsequently died. Necropsies were performed on two dogs with a pathological diagnosis of neurotoxicity determined in one and "not able to be determined" cause in the other one. These dogs also had tremors/shaking/ataxia noted as early signs of neurotoxic effects. Approximately 54 to 80% of dogs that died did not have seizures/tremors/ataxia noted in the responses.

Serious AE responses for dogs receiving isoxazolines from the Project Jake survey are summarized in Table 5, and Table 6 lists the Project Jake survey AE for those dogs receiving isoxazolines that

| Symptoms                      | Fluralaner (N = 791) | Afoxolaner (N = 235) | Sarolaner (N = 44) |
|-------------------------------|----------------------|----------------------|--------------------|
|                               | N   | %     | N   | %     | N   | %     |
| Death                         | 117 | 14.79%| 28  | 11.91%| 2   | 4.55% |
| Seizures/Convulsions          | 117 | 14.79%| 28  | 11.91%| 2   | 4.55% |
| Ataxia/Instability/Imbalance  | 116 | 14.66%| 29  | 12.34%| 6   | 13.64%|
| Shaking/Trembling             | 136 | 17.19%| 36  | 15.32%| 7   | 15.91%|
| Weakness                      | 154 | 19.47%| 37  | 15.74%| 6   | 13.64%|
| Restlessness/Anxiety         | 144 | 18.20%| 40  | 17.02%| 5   | 11.36%|
| Abnormal Feces or Stools      | 120 | 15.17%| 26  | 11.06%| 3   | 6.82% |
| Lethargy/Depression           | 248 | 31.35%| 57  | 24.26%| 8   | 18.18%|
| Panting                       | 144 | 18.20%| 40  | 17.02%| 7   | 15.91%|
| Decreased/No Appetite        | 224 | 28.32%| 52  | 22.13%| 7   | 15.91%|
| Itching/Scratching           | 119 | 15.04%| 42  | 17.87%| 2   | 4.55% |
| Vomiting                      | 169 | 21.37%| 49  | 20.85%| 4   | 9.09% |
| Diarrhea                      | 180 | 22.76%| 47  | 20.00%| 4   | 9.09% |
| Weight Loss                   | 112 | 14.16%| 21  | 8.94% | 4   | 9.09% |
| Excessive Drinking            | 137 | 17.32%| 24  | 10.21%| 5   | 11.36%|
| Decreased Water Intake        | 66  | 8.34% | 16  | 6.81% | 3   | 6.82% |
| Excessive Urination           | 71  | 8.98% | 14  | 5.96% | 1   | 2.27% |
| Flatulence                    | 31  | 3.92% | 8   | 3.40% | 0   | 0.00% |
| Hair Loss/Alopecia            | 48  | 6.07% | 18  | 7.66% | 2   | 4.55% |
| Other                         | 47  | 5.94% | 19  | 8.09% | 4   | 9.09% |
| None                          | 3   | 0.38% | 0   | 0.00% | 0   | 0.00% |

| Symptoms                      | N/ % of dogs that died that also experienced the following NS |
|-------------------------------|----------------------------------------------------------|
|                               | Fluralaner (N = 117) | Afoxolaner (N = 28) | Sarolaner (N = 2) |
|                               | N   | %     | N   | %     | N   | %     |
| Seizures/Convulsions          | 36  | 30.77%| 6   | 21.43%| 2   | 100.00%|
| Ataxia/Instability/Imbalance  | 48  | 41.03%| 13  | 46.43%| 2   | 100.00%|
| Shaking/Trembling             | 41  | 35.04%| 10  | 35.71%| 1   | 50.00% |

**TABLE 5** Isoxazoline Serious Adverse Events in Project Jake Survey

**TABLE 6** Correlation of Death With Neurological Symptoms in Project Jake Survey
#### TABLE 7 Comparison of Project Jake Survey AE to Product Package Inserts

| Fluralaner Symptoms                  | Project Jake Survey | Package Insert |
|-------------------------------------|---------------------|---------------|
|                                     | N       | %           | N     | %     |
| Decreased/No Appetite               | 224     | 28.32%      | 15    | 6.70% |
| Diarrhea                            | 180     | 22.76%      | 11    | 4.90% |
| Excessive Drinking                  | 137     | 17.32%      | 4     | 1.80% |
| Flatulence                          | 31      | 3.92%       | 3     | 1.30% |
| Lethargy/Depression                 | 248     | 31.35%      | 12    | 5.40% |
| Vomiting                            | 169     | 21.37%      | 16    | 7.10% |
| Death                               | 117     | 14.79%      | Not reported |
| Seizures/Convulsions                | 117     | 14.79%      |       |       |
| Shaking/Trembling                   | 136     | 17.19%      |       |       |
| Ataxia/Instability/Imbalance        | 116     | 14.66%      |       |       |
| Weakness                            | 154     | 19.47%      |       |       |
| Restlessness/Anxiety                | 144     | 18.20%      |       |       |
| Panting                             | 144     | 18.20%      |       |       |
| Itching/Scratching                  | 119     | 15.04%      |       |       |
| Abnormal Feces or Stools            | 120     | 15.17%      |       |       |
| Weight Loss                         | 112     | 14.16%      |       |       |
| Decreased Water Intake              | 66      | 8.34%       |       |       |
| Excessive Urination                 | 71      | 8.98%       |       |       |
| Hair Loss/Alopecia                  | 48      | 6.07%       |       |       |
| Total                               | 791     | 100%        | 224   | 100%  |

| Afoxolaner Symptoms                 | Project Jake Survey | Package Insert |
|-------------------------------------|---------------------|---------------|
|                                     | N       | %           | N     | %     |
| Decreased/No Appetite               | 52      | 22.13%      | 5     | 1.20% |
| Diarrhea                            | 47      | 20.00%      | 13    | 3.10% |
| Lethargy/Depression                 | 57      | 24.26%      | 7     | 1.70% |
| Vomiting                            | 49      | 20.85%      | 17    | 4.10% |
| Dry/Flaky Skin                      | Not reported      | 13            | 3.10% |
| Death                               | 29      | 12.34%      | Not reported |
| Seizures/Convulsions                | 28      | 11.91%      |       |       |
| Shaking/Trembling                   | 36      | 15.32%      |       |       |
| Ataxia/Instability/Imbalance        | 26      | 11.06%      |       |       |
| Weakness                            | 37      | 15.74%      |       |       |
| Restlessness/Anxiety                | 40      | 17.02%      |       |       |
| Panting                             | 40      | 17.02%      |       |       |
| Itching/Scratching                  | 42      | 17.87%      |       |       |
| Abnormal Faeces or Stools           | 26      | 11.06%      |       |       |
| Weight Loss                         | 21      | 8.94%       |       |       |
| Excessive Drinking                  | 24      | 10.21%      |       |       |
| Decreased Water Intake              | 16      | 6.81%       |       |       |
| Excessive Urination                 | 14      | 5.96%       |       |       |
| Hair Loss/Alopecia                  | 18      | 7.66%       |       |       |
| Total                               | 235     | 100.00%     | 415   | 100.00% |

*Package Inserts are available in Appendix B.
died after experiencing seizures or other neurological symptoms. However, not all dogs presenting with seizures, ataxia, instability, imbalance, shaking and trembling progressed to death (Table 6).

The number of AE reported by respondents in the Project Jake survey is shown in Table 7 compared to those AE listed in the manufacturer package inserts for fluralaner and afoxolaner. This tabulation demonstrates that no serious AE are listed in the inserts for either drug (Table 7). Serious neurological AE findings from the FDA, EMA and Project Jake survey are consolidated in Table 8. Although the number of AE reported to the FDA (32,374) and EMA (39,148) is essentially comparable, a 7 to 10 times higher occurrence of death and seizure was reported to the EMA from territories outside the United States. The source of AE reports should be compared, namely the percentage of reports received from veterinarians versus pet owners. The reports of death and seizure for lotilaner and spinosad are noteworthy with respect to product labels and inserts for potential neurological effects, as shown in the Appendix. The reported responses for the Project Jake survey for death and seizure observations were significantly higher than in the FDA dataset and comparable to the findings from the EMA reports (Deaths: EMA = 14.19%, Project Jake = 13.74%; Seizures: EMA = 16.02%, Project Jake = 13.74% (Tables 6 and 8).

### 3.4 Statistical analysis

The Project Jake survey percentages of AE were below those reported by the EMA but much higher than those reported by the FDA. However, the p-values for the two-tailed Z-test differences between the Project Jake survey and fluralaner, afoxolaner and sarolaner for both the FDA and EMA reported AE were all < 0.00001. The statisticians in our group have indicated that an in-depth statistical analysis of the rest of the survey findings would not be applicable to this type of survey.

### 4 DISCUSSION

The Project Jake survey results shown here differed from those of the FDA and EMA AE reports in several ways, namely: (1) Pet caregivers/owners surveyed included those that did not see any AE, as well as those that did report them, providing a more unbiased review of isoxazoline use; (2) Survey included observations pre- (3 months) and post-drug use; (3) Questioned when AE occurred after use of the drug; (4) Questioned number of doses of drug(s) given before

---

**TABLE 8** Summary of Serious Adverse Events Reported in FDA, EMA and Project Jake Surveys

| Events Reported | Number and Percent of Sample Population Displaying Reaction |
|-----------------|-----------------------------------------------------------|
|                 | Jan 2013–Sept 2017 Overall (N = 32,374) Fluralaner (N = 16,896) Afoxolaner (N = 14,116) Sarolaner (N = 1,361) |
| Death           | 801 2.47% 416 2.50% 341 2.40% 44 3.20% |
| Seizure         | 1,728 5.34% 468 2.80% 981 6.90% 279 20.50% |
| Shaking/Tremors/Ataxia | 2,223 6.87% 600 3.60% 1,063 7.50% 560 41.10% |

| Jake Survey Serious Adverse Events Results |
|--------------------------------------------|
| Events/Symptoms                            |
| Overall (N = 1,070)                         |
| Fluralaner (N = 791)                        |
| Afoxolaner (N = 235)                        |
| Sarolaner (N = 44)                          |
| Death                                      |
| 147 13.74% 117 14.79% 28 11.91% 2 4.55%  |
| Seizures/Convulsions                       |
| 147 13.74% 117 14.79% 28 11.91% 2 11.14% |
| Shaking/Tremors/Ataxia                     |
| 493 43.2% 271 34.3% 178 75.7% 13 29.6%  |

| EMA Serious Adverse Events Results |
|-----------------------------------|
| Event(s) Reported Jan 2013-2019    |
| Overall (N = 39,148)               |
| Fluralaner (N = 10,172)            |
| Afoxolaner (N = 20,902)            |
| Sarolaner (N = 1917)               |
| Death                             |
| 5,556 14.19% 2,408 23.7% 528 22.68% 250 13.04% |
| Seizure                           |
| 6,272 16.02% 1,860 18.30% 1,087 46.69% 1,055 55.1% |

| EMA Serious Adverse Events Results |
|-----------------------------------|
| Event(s) Reported Jan 2013-2019    |
| Overall (N = 39,148)               |
| Fluralaner (N = 10,172)            |
| Afoxolaner (N = 20,902)            |
| Sarolaner (N = 1917)               |
| Credelio (N = 77)                  |
| N%                                |
| 22 28.60% 1882 30.9%               |
| Comfortis (N = 6,084)              |
| N%                                |
| 21 27.60% 1,460 24.00%             |
AE; (5) Other concurrent health issues and treatments given were requested; (6) Multiple AE were listed for each report; (7) Recovery information and/or follow-ups were included.

The consolidated FDA, Project Jake and EMA findings (Table 8) showed notable differences between survey populations regarding the percentage of neurological toxicity and serious AE, and fatal effects. Statistical analysis of these serious AE showed highly significant differences between the findings of the Project Jake survey and those reported by the FDA and EMA. While the number of death and seizure AE reported by the EMA was 7 to 10 times higher than those reported to the FDA, the reported responses for the Project Jake survey for death and seizures fell in between those of the FDA and EMA but aligned more closely with the EMA results. Furthermore, the number of reported death and seizure AE for lotilaner and spinosad were considerably higher than suggested with respect to their product labelling for potential neurological effects (Table 2 and 8). Based on the results from the Project Jake survey and reviews of publicly available FDA and EMA AE reports demonstrating that cross-species neurotoxicity exists, the following issues also require further attention: Recognition of human exposure risk as delineated in package inserts, and concerns that may arise from recent proposals to repurpose isoxazoline veterinary drugs for application to vector-borne human diseases by treating humans (Miglianico et al., 2018). Furthermore, there is a very real potential for food-chain associated AE, since fluralaner (as Exzolt) has recently been approved for treatment in poultry in Europe (Exzolt fluralaner for chickens: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/veterinary/medicines/004344/vet_med_000353.jsp&mid=nonbreakingspace=nonbreakingspace=Exzolt%20G tempting%20emb predecessor%20breakingspace=nonbreakingspace=WCOb01ac058008d7a).

Our review of the FDA and EMA AE reports has generated a list of questions and safety concerns: A warning has been sent out in September 2018 by the US FDA to alert pet owners and veterinarians to be aware of the potential for neurological adverse events in dogs and cats when treated with drugs that are in the isoxazoline class. The FDA has since requested that manufacturers of isoxazoline products to include new label information to highlight neurological effects because these events were seen consistently across the isoxazoline class of products. Subsequently the FDA has updated the alert with additional manufacturer information in April 2019, August 2019 and October 2019.

Based upon the FOIA FDA and EMA summary findings and implications, the death and seizure rate differences noted for the EMA were about 3–10 times higher than the FDA (Table 8). Were these FDA and EMA AE reports filed by veterinarians or by pet caregivers/owners or both? Additionally, analysis of the EMA data indicated that more than 60% of canine deaths and 55% of seizures were in dogs > 5 years of age (Table 9), but information regarding concomitant disease or other treatments was unavailable. Finally, no FDA or EMA data were available to determine whether most dogs that died also had preceding seizures, nor were we able to establish the time to death, and onset of or recovery from seizures. In that regard, the latest update from the FDA states "Isoxazoline products have been associated with neurologic adverse reactions, including muscle tremors, ataxia and seizures in some dogs and cats. Although most dogs and cats haven't had neurologic adverse reactions, seizures may occur in animals without a prior history."

In the Project Jake survey, although not all dogs presenting with ataxia, instability, tremors and/or seizures progressed to death, for the dogs that died, about 21 to 31% also had seizures (Table 6). Survey responders did not indicate the recovery status from these neurological effects. However, several isolated reports (private communications with the authors of which three are veterinarians have indicated extended long-term neurologic signs with incomplete amelioration).
The recent FDA Center for Veterinary Medicine (CVM) has a “Fact Sheet for Pet Owners and Veterinarians about Potential Adverse Events Associated with Isoxazoline Flea and Tick Products”. In this publication, the FDA is alerting pet owners and veterinarians of the potential for neurological adverse events in dogs and cats when treated with drugs that are in the isoxazoline class. However, the FDA considers products in the isoxazoline class to be safe and effective for dogs and cats. Although most dogs and cats have not experienced neurological AE reactions, the FDA states that seizures may occur in animals without a prior history (FDA, https://www.fda.gov/AnimalVeterinary/ResourcesForYou/AnimalHealthLiteracy/ucm620940.htm). The FDA is working with manufacturers of isoxazoline products to include new label information to highlight neurological events because these events have been seen consistently across the isoxazoline class of products (FDA, https://www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm620934.htm). Changes in Package labelling since September 2018 are contained in the Appendix.

In conclusion, isoxazolines exhibit killing activity through effects on the insect nervous system. Prior reports (Gassel et al., 2014) showed that the isoxazoline fluralaner did not demonstrate any inhibitory action on the GABACl channels of rats and suggested that fluralaner is a potent arthropod - specific GABACl channel inhibitor.

However, FDA and EMA AE reports and Project Jake survey evidence consistently demonstrate in three separate, distinct data sets that the neurotoxicity is not arthropod-specific, and that post-marketing serious AE are much higher than in the IND submission studies. Thus, as a class of drugs, these data indicate that isoxazolines can work as intrinsic neurotoxins across species. As pre-approval IND studies were done in only a limited number of animals that did not show neurotoxic serious AE, it is not surprising that higher frequencies of such AE were noted once they were commercialized and given to much larger populations.

The data also suggested notable differences in reporting of AE for the US versus European territories. This may reflect cultural tendencies and/or procedural methodologies for reporting of AE. Nevertheless, the national and international post-market safety survey data summarized here indicate an immediate need for continued cross-species studies and a critical review of product labelling by regulatory agencies and manufacturers. Moreover, this class of drugs had more serious AE than those reported in the package inserts. We believe that the FDA should consider additional changes to their criteria for AE observation, and define what would be needed for future clearances of this class of drugs.

CONFLICT OF INTEREST
The authors disclose no financial interest nor conflicts-of-interest in the present study.

AUTHOR CONTRIBUTIONS
W. Jean Dodds: Conceptualization; Formal analysis; Investigation; Methodology; Validation; Writing-original draft; Writing-review & editing. Valerie Palmieri: Conceptualization; Funding acquisition; Project administration; Writing-original draft; Writing-review & editing. Judy Morgan: Writing-original draft. Elizabeth Carney: Writing-original draft. Herbert A. Fritsche: Writing-original draft. Jaclyn Jeffrey: Validation; Writing-original draft. Rowan Bullock: Formal analysis; Methodology; Writing-original draft; Writing-review & editing. Jon P Kimball: Formal analysis; Investigation; Methodology; Validation; Writing-original draft; Writing-review & editing.

REFERENCES
Drag, M., Saik, J., Harriman, J., & Larsen, D. (2014). Safety evaluation of orally administered afoxolaner in 8-week-old puppies. Veterinary Parasitology, 201, 198–203. https://doi.org/10.1016/j.vetpar.2014.02.022
Evans, J. R., & Mathur, A. (2018). The value of online surveys: A look back and a look ahead. Internet Research, 27(4), 854–887. https://doi.org/10.1108/IntR-03-2018-0089
Gaens, D., Rummel, C., Schmidt, M., Hamann, M., & Geyer, J. (2019). Case report. Suspected neurological toxicity after oral application of fluralaner (Bravecto®) in a Kooikerhondje dog. BMC Veterinary Research, 15, 283. doi.org/10.1186/s12917-019-2016-4.
Garcia-Reynaga, P., Zhao, C., Sarpong, R., & Casida, J. E. (2013). New GABA/glutamate receptor target for [3H] isoxazoline insecticide. Chemical Research in Toxicology, 26(4), 514–516. https://doi.org/10.1021/tr400055p
Gassel, M., Wolf, C., Noack, S., Williams, H., & Ilg, T. (2014). The novel isoxazoline ectoparasiticide fluralaner: Selective inhibition of arthropod γ-aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/acericidal activity. Insect Biochemistry and Molecular Biology, 45, 111–124. https://doi.org/10.1016/j.ibmb.2013.11.009
Kuntz, E. A., & Kammanadimitri, S. (2017). Safety evaluation of lotilaner in dogs after oral administration as flavoured chewable tablets (Credelio®). Parasites & Vectors, 10, 538. https://doi.org/10.1186/s13071-017-2468-y
Letendre, L., Huang, R., Kvatternick, V., Harriman, J., Drag, M., & Soll, M. (2014). The intravenous and oral pharmacokinetics of afoxolaner used as a monthly chewable antiparasitic for dogs. Veterinary Parasitology, 210 (3–4), 190–197. https://doi.org/10.1016/j.vetpar.2014.02.021
Miglianico, M., Eldering, M., Slater, H., Ferguson, N., Ambrose, P., Lees, R. S., ... Dechering, K. J. (2018). Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases. Proceedings of the National Academy of Sciences, 115(29), E6920–E6926. https://doi.org/10.1073/pnas.1801338115
Nakata, Y., Fuse, T., Yamato, K., Asahi, M., Nakahira, K., Ozoe, F., & Ozoe, Y. (2017). A single amino acid substitution in the third transmembrane region has opposite impacts on the selectivity of the Parasiticide Fluralaner and Ivermectin for ligand-gated chloride channels. Molecular Pharmacology, 92(5), 546–555. https://doi.org/10.1124/mol.117.109413
Nayak, M. S. D. P., & Narayan, K. A. (2019). Strengths and weakness of online surveys. Journal of Humanities and Social Science, 24(5), 31–38.
Ozoe, Y., Ozoe, F., Nakahira, K., & Mita, T. (2010). The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels. Biochemical and Biophysical Research Communications, 391(1), 744–749. https://doi.org/10.1016/j.bbrc.2009.11.131
Quan, M. L., Ellis, C. D., Liauw, A. Y., Alexander, R. S., Knabb, R. M., Lam, G., ... Wexler, R. R. (1999). Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. *Journal of Medicinal Chemistry*, 42, 2760–2773. https://doi.org/10.1021/jm980406a

Rice, S., Winter, S. R., Doherty, S., & Milner, M. (2017). Advantages and disadvantages of using internet-based survey methods in aviation-related research. *Journal of Aviation Technology and Engineering*, 7(1), 58–65. https://doi.org/10.7771/2159-6670.1160

Saidjiam, M., Dermani, F. K., Sohrabi, S., Patching, S. G. (2017). Efflux proteins at the blood–brain barrier: review and bioinformatics analysis. *Topics in Xenobiochemistry*, 506–552. https://doi.org/10.1080/00498276.2017.1328148

Shoop, W. L., Hartline, E. J., Gould, B. R., Waddell, M. E., McDowell, R. G., Kinney, J. B., ... Confalone, P. N. (2014). Discovery and mode of action of afoxalaner, a new isoxazoline parasiticide for dogs. *Veterinary Parasitology*, 213(3–4), 179–189. https://doi.org/10.1016/j.vetpar.2014.02.020

Vaske, J. J. (2011). Advantages and disadvantages of internet surveys: Introduction to the special issue. *Human Dimensions of Wildlife*, 16(3), 149–153. https://doi.org/10.1080/10871209.2011.572143

Zhao, C., & Casida, J. E. (2014). Insect gamma-aminobutyric acid receptors and isoxazoline insecticides: Toxicological profiles relative to the binding sites of [(3)H] fluralaner, [(3)H]-4′-ethynyl-4-n-propylbicycloorthobenzoate, and [(3)H] avermectin. *Journal of Agricultural and Food Chemistry*, 62(5), 1019–1024. https://doi.org/10.1021/jf4050809

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: PalmieriV, Dodds WJ, Morgan J, et al. Survey of canine use and safety of isoxazoline parasiticides. *Vet Med Sci*. 2020;6:933–945, [https://doi.org/10.1002/vms3.285](https://doi.org/10.1002/vms3.285)

**APPENDIX**

**PROJECT JAKE SURVEY INSTRUMENT, 2018 (COPY ATTACHED)**

**FOIA Requests:** Afoxolaner\(^1\)/Fluralaner\(^2\)/Sarolaner\(^6\) [Isoxazoline Side Effects FDA Adverse Reaction Reports]

1. FDA-CVM FOIA Response 2015–4864, Nov 2015; CVM ADE Comprehensive Clinical Detail Report Listing, Cumulative Date Range: 01-Jan-2013 - thru- 17-Jun-2015
2. FDA-CVM FOIA Response 2016–96, Jan 2016; CVM ADE Comprehensive Clinical Detail Report Listing, Cumulative Date Range: 18-Jun-2015 to 06-Jan-2016
3. FDA-CVM FOIA Response 2016–2546, May 2016; CVM ADE Comprehensive Clinical Detail Report Listing, Cumulative Date Range: 07-Jan-2016 to 31-Mar-2016
4. FDA-CVM FOIA Response 2016–6026, July 2016; CVM ADE Comprehensive Clinical Detail Report Listing, Cumulative Date Range: 04-Apr-2016 to 15-Jul-2016
5. FDA-CVM FOIA Response 2016–8391, Nov 2016; CVM ADE Comprehensive Clinical Detail Report Listing, Cumulative Date Range: 16-Jul-2016 to 15-Oct-2016
6. FDA-CVM FOIA Response 2017–963, Feb 2017; CVM ADE Comprehensive Clinical Detail Report Listing, Cumulative Date Range: 16-Oct-2016 to 26-Jan-2017
7. FDA-CVM FOIA Response 2017–4111, May 2017; CVM ADE Comprehensive Clinical Detail Report Listing, Cumulative Date Range: 28-Jan-2017 to 2-May-2017
8. FDA-CVM FOIA Response 2017–8858, Oct 2017; CVM ADE Comprehensive Clinical Detail Report Listing, Cumulative Date Range: 03-May-2017 to 30-Sept-2017
9. EMA – Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 5–7 September 2017; Cumulative Reports from Jan 2013 – Sept 2017. [https://www.ema.europa.eu/en/news/committee-medicinal-products-veterinary-use-cvmp-meeting-5-7-september-2017](https://www.ema.europa.eu/en/news/committee-medicinal-products-veterinary-use-cvmp-meeting-5-7-september-2017)

**EXCERPTS FROM US PACKAGE INSERTS STATE ‘SEIZURE’ AS ADDITION TO ISOXAZOLINE LABELS AFTER SEPTEMBER 2018**

**Precautions**

- **Afoxolaner** (Nexgard®, Frontline Vet Labs™, Div. Merial Inc., Duluth, GA) is a member of the isoxazoline class. This class has been associated with neurological adverse reactions including tremors, ataxia and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurological disorders.

- **Fluralaner** (Bravecto®, Merck Animal Health, Madison, NJ). Important Safety Information (for Veterinarians): Use caution in dogs with a history of seizures. Seizures have been reported in dogs receiving fluralaner, even in dogs without a history of seizures. [in 2019 Canada label: Neurological disorders: convulsions, ataxia, muscle tremor]

- **Sarolaner** (Simparica™, Zoetis Inc, Kalamazoo, MI) may cause abnormal neurological signs such as tremors, decreased conscious proprioception, ataxia, decreased or absent menace, and/or seizures.

- **Lotilaner** (Credelio®, Elanco US, Greenfield, IN) The safe use of lotilaner in breeding, pregnant or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures.

- **Spinosad** (Comfortis®, Elanco US, Greenfield, IN) Post Approval Experience (June 2009): The following adverse reactions are based on post-approval adverse drug event reporting. The adverse reactions are listed in decreasing order of frequency: vomiting, depression/lethargy, anorexia, ataxia, diarrhea, pruritus, trembling, hypersalivation and seizures.

- A spinosyns class of insecticides, which are non-antibacterial tetraacylic macrolides

All products have warnings against human exposure.
Prior to the FDA alert informing pet owners and veterinarians of potential for neurological adverse events for isoxazolines on September 21, 2018 product labelling did not contain precautionary or warning labelling of these AE. The excerpted statements are representative of (slightly) modified package labels containing cursory comments related to seizures. The Canadian fluralaner label version of 2019 lists seizure with the qualifier of occurrence rates of less than 1 in 10,000.

Fluralaner 2019 package labelling in Canada states: “The following adverse events have been reported rarely: 1 (reported in at least 1 but not more than 10 animals in 10,000 animals exposed) and very rarely: 2 (reported in less than 1 in 10,000 animals exposed) and are listed by body system, in decreasing order of frequency: Digestive tract disorders: vomiting, diarrhoea, hypersalivation, haemorrhagic diarrhoea Systemic disorders: lack of efficacy, lethargy, anorexia Skin and appendage disorders: pruritus, alopecia Neurological disorders: convulsions, ataxia, muscle tremor.”